An interventional study of EndoTEM resection platform and technique in Adenoma Colon Polyp and Adenoma Colon, sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF). Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Polyps with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Polyps · Germany.
Among the 22 studies in Polyps with a site in Germany, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 22nd registered.
312 studies on the registry are indexed under Polyps; 59 are open to participants now.
Browse Polyps studies →4 of the 22 studies in Polyps with a site in Germany are open now. Recruiting first, the newest first:
Rapamycin Holdings Inc. · Sites in Germany, United States, Denmark and 4 more countries
Ages 18+
Helios Kliniken Schwerin · Sites in Germany
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 35+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 34 Polyps studies recruiting now, 25 (74%) set no upper age limit and 6 (18%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 150 across 204 interventional studies indexed under Polyps.
Median enrollment 225 across the 13 interventional studies, 600 across the 9 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) has 1 study filed under Polyps — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Polyps with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon is feasible and safe.
The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Utilization of the EndoTEM system in the performance of routine endoscopic en bloc resection using endoscopic submucosal dissection.
Device: EndoTEM resection platform and technique
EndoTEM is a flexible transanally introduced port system that allows the insertion of a second instrument alongside the flexible endoscope. A curved rigid grasping instrument has been developed, with a 2 cm long tip that can be rotated and angled in all directions.
Also known as: endoscopic portsystem
Technical success of the endoscopic resection
Macroscopically complete resection.
Time frame: From the endoscopic resection to the follow-up endoscopy after 6 months.
R0 resection rate
Histological complete resection.
Time frame: Assessed with a biopsy collected during the intervention.
En bloc resection rate
Endoscopic removal of the polyp in one intact piece, including any necessary surrounding tissue.
Time frame: Assessed during the intervention.
Duration of the procedure
Time frame: From endoscope insertion until the end of procedure including supplementary and prophylactic interventions.
Resection time
Time frame: From start of the resection until detachment of the specimen.
Resection speed
Resected area per minute (mm²/min).
Time frame: Assessed during the intervention.
Periprocedural complications
Time frame: Complications that occur during or immediately around the intervention (until 3-6 months post-intervention).
Requirement for surgical intervention
Time frame: During the endoscopic submucosal dissection.
Rate of recurrence
Time frame: Assessed during follow-up endoscopy 3-6 months post-intervention.
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.
Of 68 non-industry interventional studies with no phase under Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 34 months is above that.
Counting every sponsor, half of 79 studies reached it within 23 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)